Abstract: Methods and materials are described for human genome prophylaxis and therapy of diseases using myoblast transfer. These methods result in gene transcript changes in multiple pathways. Linking the myoblast transfer technology development from DMD, cardiomyopathy, and Type-II diabetes, the myoblast transfer demonstrably mediates its effect through transfer of the normal myoblast nuclei that supply the complete human genome, in addition to just replenishing the missing gene(s) or the aberrant gene(s). The replacement genes then transcribe to produce the necessary proteins or factors for genetic repair. A variety of uses of this technology are described, including that for disease treatment, disease prevention, drug discovery, and selection of superior cells and clones for therapy.

Abstract: A composition having a quantum of genetically normal non-host myoblasts and host serum, wherein the composition is adapted to induce myoblast proliferation. Also, disclosed is a method for inhibiting growth of a cancer tumor in a host and/or preventing cancer cells from metastasis in a host.

Abstract: The invention is directed to a composition having a quantum of genetically normal non-host myoblasts and host serum, wherein the composition is adapted to induce myoblast proliferation. The invention is also directed to a composition for use as a medicament and a composition for use in inhibiting growth of a cancer tumor in a host and/or preventing cancer cells from metastasis in a host.

Abstract: Methods and materials are described for human genome prophylaxis and therapy of diseases using myoblast transfer. These methods result in gene transcript changes in multiple pathways. Linking the myoblast transfer technology development from DMD, cardiomyopathy, and Type-II diabetes, the myoblast transfer demonstrably mediates its effect through transfer of the normal myoblast nuclei that supply the complete human genome, in addition to just replenishing the missing gene(s) or the aberrant gene(s). The replacement genes then transcribe to produce the necessary proteins or factors for genetic repair.

Abstract: Methods and materials are described for human genome prophylaxis and therapy of diseases using myoblast transfer. These methods result in gene transcript changes in multiple pathways. Linking the myoblast transfer technology development from DMD, cardiomyopathy, and Type-II diabetes, the myoblast transfer demonstrably mediates its effect through transfer of the normal myoblast nuclei that supply the complete human genome, in addition to just replenishing the missing gene(s) or the aberrant gene(s). The replacement genes then transcribe to produce the necessary proteins or factors for genetic repair.

Abstract: Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted/released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells.

Abstract: An analgesic benefit is realized by continuously supplying a peptide in vivo that activates an opioid receptor or that interferes with the binding of substance P to its receptors. The long-term, continuous provision of such a peptide can be accomplished by (a) transducing myogenic cells with DNA expressing the peptide and (b) administering the transduced myogenic cells to a patient, such that the cells continuously produce the peptide.

Abstract: Myoblast cells obtained by culturing, particularly from satellite cells or other progenitor cells, are transplanted into tissue such as diseased heart tissue to form healthy repair tissue and reverse disease. This technique can be carried out in various ways and preferably includes a cellular integration factor to assist cellular survival, integration and longevity into the treated organ. Angiogenesis factors such as vascular endothelial growth factor are particularly preferred and may be transgenically expressed by the transplanted cell. Other factors that may be used to augment the procedure include migratory and scaffolding molecules. The methods and materials are particularly useful in combination with an automated cell processor and an automated catheter delivery system. The materials and methods for their use may be applied to the prophylaxis and therapy of damaged hearts, using cells originally obtained from the patient, another human, or another animal.

Abstract: An analgesic benefit is realized by continuously supplying a peptide in vivo that activates an opioid receptor or that interferes with the binding of substance P to its receptors. The long-term, continuous provision of such a peptide can be accomplished by (a) transducing myogenic cells with DNA expressing the peptide and (b) administering the transduced myogenic cells to a patient, such that the cells continuously produce the peptide.

Abstract: Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted/released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells.

Abstract: Compositions and methods of treating mammalian diseases using myoblasts, and/or their physical, genetic, chemical derivatives. Myogenic cells that are normal, or genetically or phenotypically altered are cultured and transplanted into malfunctioning and/or degenerative tissues or organs to alleviate conditions that are hereditary, degenerative, debilitating, undesirable, and/or fatal. Treatment of these conditions is not limited to the usage of mechanical, electrical or physical properties of these myogenic cells, but includes the usage of biochemicals secreted/released by the latter. The present invention discloses the use of normal myoblasts to deliver the complete normal genome to effect genetic repair, or to augment the size, or the function of tissues or organs. Certain conditions may be better served with genetically altered myogenic cells derived from gene transduction, whereas others may be better served with cytoclimes converter cells.

Abstract: Compositions for and methods of treating muscle weakness and degeneration are described. Such compositions include myogenic cells which are administered by the described methods to one or more affected muscles.